Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW A LUNNING

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1003935081
CMS profile
45615
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$97,383.88

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Kite Pharma, Inc. $23,962.62 13
Seagen Inc. $12,374.21 11
Ipsen Biopharmaceuticals, Inc $12,279.60 4
Epizyme, Inc. $9,712.00 2
E.R. Squibb & Sons, L.L.C. $9,314.02 8
Genentech USA, Inc. $6,977.58 7
Gilead Sciences, Inc. $4,485.31 5
ABBVIE INC. $3,853.32 11
Lilly USA, LLC $3,600.00 1
Genmab U.S., Inc. $3,593.32 5
AstraZeneca Pharmaceuticals LP $2,392.19 4
ADC Therapeutics America, Inc. $1,910.88 3
Takeda Pharmaceuticals U.S.A., Inc. $1,625.00 1
Daiichi Sankyo Inc. $645.00 1
Acrotech Biopharma Inc. $325.00 1
BeiGene USA, Inc. $205.49 2
Celgene Corporation $128.34 2

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW A LUNNING

NPI 1003935081 · CMS profile ID 45615

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003935081?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW A LUNNING, NPI 1003935081, CMS profile ID 45615. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003935081?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MATTHEW A LUNNING, NPI 1003935081, CMS profile ID 45615. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003935081?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MATTHEW A LUNNING, NPI 1003935081, CMS profile ID 45615, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003935081?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $97,383.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Seagen Inc. $200.0005/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995691943 CMS
Seagen Inc. $108.1405/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995691719 CMS
E.R. Squibb & Sons, L.L.C. $1,779.0004/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014899639 CMS
Kite Pharma, Inc. $3,170.0004/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271071 CMS
AstraZeneca Pharmaceuticals LP $2,055.0004/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011865593 CMS
Genentech USA, Inc. $2,500.0004/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040457555 CMS
Kite Pharma, Inc. $8,280.0004/07/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271069 CMS
ADC Therapeutics America, Inc. $150.8803/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053783507 CMS
AstraZeneca Pharmaceuticals LP $100.2003/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011794071 CMS
BeiGene USA, Inc. $168.8503/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051177497 CMS
Ipsen Biopharmaceuticals, Inc $2,070.0003/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045419555 CMS
E.R. Squibb & Sons, L.L.C. $444.7503/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014899599 CMS
Kite Pharma, Inc. $25.0003/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271075 CMS
Kite Pharma, Inc. $25.0003/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271077 CMS
Kite Pharma, Inc. $28.4803/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271079 CMS
Kite Pharma, Inc. $50.0003/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271081 CMS
Kite Pharma, Inc. $50.0003/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271083 CMS
Kite Pharma, Inc. $52.0003/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271091 CMS
Kite Pharma, Inc. $32.2203/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271073 CMS
Kite Pharma, Inc. $426.9303/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271085 CMS
Kite Pharma, Inc. $470.8903/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271087 CMS
Kite Pharma, Inc. $1,272.1003/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025271089 CMS
Epizyme, Inc. $4,882.0003/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 981306987 CMS
E.R. Squibb & Sons, L.L.C. $3,542.5003/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014899547 CMS
Lilly USA, LLC $3,600.0002/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031795525 CMS
Epizyme, Inc. $4,830.0002/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 981306985 CMS
Acrotech Biopharma Inc. $325.0001/30/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052991853 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,625.0001/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055464049 CMS
E.R. Squibb & Sons, L.L.C. $568.0001/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014899447 CMS
ABBVIE INC. $550.0001/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997802335 CMS
Daiichi Sankyo Inc. $645.0001/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006573357 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $79,726.21 95
PY2020 $60,060.46 41
PY2021 $54,411.05 29
PY2022 $111,236.13 96
PY2023 $97,383.88 81
PY2024 $146,366.79 86
PY2025 $81,954.63 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,231.83 3
PY2025 Principal investigator $599,062.07 14
PY2024 Principal investigator $98,348.43 13
PY2023 Principal investigator $357,492.68 18
PY2022 Principal investigator $549,677.35 28
PY2021 Principal investigator $366,268.92 13
PY2020 Principal investigator $700,094.42 17
PY2019 Recipient $3,298.00 1
PY2019 Principal investigator $2,189,582.76 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
UNEHEALTH
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies No dispute reported 06/30/2026 1202533205
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $205.00 11/05/2025 Non-covered Recipient Entity
Unehealth
Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release No dispute reported 06/30/2026 1235992759
Principal investigator 1 ABBVIE INC. $7,840.64 10/22/2025 Non-covered Recipient Entity
UNEHEALTH
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202518181
Principal investigator 1 Kite Pharma, Inc. $4,066.00 10/14/2025 Non-covered Recipient Entity
UNEHEALTH
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212071125
Principal investigator 1 Kite Pharma, Inc. $14,208.00 10/14/2025 Non-covered Recipient Entity
UNEHEALTH
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212071129
Principal investigator 1 Eli Lilly and Company $19,678.00 10/09/2025 Non-covered Recipient Entity
UNEHEALTH
LONG-TERM SAFETY OF PIRTOBRUTINIB IN PARTICIPANTS FROM STUDY LOXO-BTK-18001 WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1187891636
Principal investigator 1 Celgene Corporation $2,766.95 10/08/2025 Non-covered Recipient Entity
Unehealth
Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release No dispute reported 06/30/2026 1222307227
Recipient Regeneron Pharmaceuticals, Inc. $468.41 08/25/2025 Covered Recipient Physician AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184119833
Principal investigator 1 Kite Pharma, Inc. $2,560.00 07/22/2025 Non-covered Recipient Entity
UNEHEALTH
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel No dispute reported 06/30/2026 1212071121
Principal investigator 1 Celgene Corporation $176,317.68 06/18/2025 Non-covered Recipient Entity
Unehealth
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) No dispute reported 06/30/2026 1222306799
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $331,845.36 06/18/2025 Non-covered Recipient Entity
Unehealth
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) No dispute reported 06/30/2026 1235992757
Recipient Regeneron Pharmaceuticals, Inc. $495.21 06/01/2025 Covered Recipient Physician AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184119831
Principal investigator 1 Kite Pharma, Inc. $1,500.00 04/01/2025 Non-covered Recipient Entity
UNEHEALTH
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212071116
Recipient Regeneron Pharmaceuticals, Inc. $268.21 03/25/2025 Covered Recipient Physician AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184119829
Principal investigator 1 Kite Pharma, Inc. $14,208.00 02/04/2025 Non-covered Recipient Entity
UNEHEALTH
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel No dispute reported 06/30/2026 1212071112
Principal investigator 1 Celgene Corporation $10,997.00 01/17/2025 Non-covered Recipient Entity
Unehealth
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. No dispute reported 06/30/2026 1222306865
Principal investigator 1 ABBVIE INC. $12,269.44 01/08/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202429227